Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38

Brain

Volumn 137, Issue 3, 2014, Pages 779-794

  Amin, Faisal Mohammad ^a   Hougaard, Anders ^a   Schytz, Henrik W ^a   Asghar, Mohammad S ^a   Lundholm, Elisabet ^a   Parvaiz, Arushma I ^a   De Koning, Patrick J H ^b   Andersen, Malene R ^a   Larsson, Henrik B W ^a   Fahrenkrug, Jan ^c   Olesen, Jes ^a   Ashina, Messoud ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

human pain models; imaging; migraine pathogenesis

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; TRYPTASE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABNORMAL SENSATION; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BRAIN ARTERY; BREATHING RATE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DILATATION; DIZZINESS; DOUBLE BLIND PROCEDURE; END TIDAL CARBON DIOXIDE TENSION; ENZYME BLOOD LEVEL; FACE DISORDER; FACIAL PUFFING; FEMALE; FINGER TINGLING; FLUSHING; HAND DISEASE; HAND PARESTHESIA; HAND SWELLING; HEADACHE; HEART PALPITATION; HEART RATE; HEAT SENSATION; HUMAN; INCIDENCE; JAW PAIN; MAGNETIC RESONANCE ANGIOGRAPHY; MENINGEAL ARTERY; MIDDLE CEREBRAL ARTERY; MIGRAINE; MIGRAINE AURA; NAUSEA; NOSE OBSTRUCTION; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHIVERING; SUPERFICIAL TEMPORAL ARTERY; THORAX DISEASE; THORAX TINGLING; THROAT DISEASE; THROAT SWELLING; VASODILATATION; VISUAL DISORDER; VOMITING; XEROSTOMIA; YAWNING; YOUNG ADULT;

HUMAN PAIN MODELS; IMAGING; MIGRAINE PATHOGENESIS;

ADULT; CEREBRAL ARTERIES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MIGRAINE DISORDERS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; TRYPTASES; VASOACTIVE INTESTINAL PEPTIDE; YOUNG ADULT;

EID: 84894565383     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt369     Document Type: Article

References (51)

1. Altman DG. Practical statistics for medical research. Boca Raton, FL: CRC Press LLC; 1999.
2. Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 2012; 32: 140-9.
3. Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJH, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 2013a; 12: 454-61.
4. Amin FM, Asghar MS, Ravneberg JW, de Koning PJH, Larsson HBW, Olesen J, Ashina M. The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers. Cephalalgia 2013b; 33: 1009-16.
5. Amir-Zilberstein L, Blechman J, Sztainberg Y, Norton WH, Reuveny A, et al. Homeodomain protein otp and activity-dependent splicing modulate neuronal adaptation to stress. Neuron 2012; 73: 279-91.
6. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, van der Koning P, Larsson HBW, et al. Evidence for a vascular factor in migraine. Ann Neurol 2011; 69: 635-45.
7. Baun M, Olesen J, Jansen-Olesen I. Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. Eur J Pharmacol 2011; 670: 186-94.
8. Baun M, Pedersen MHF, Olesen J, Jansen-Olesen I. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia 2012; 32: 337-45.
9. Birk S, Petersen KA, Kruuse C, Guieu R, Jonassen O, Eisert W, et al. The effect of circulating adenosine on cerebral hemodynamics and headache generation in healthy subjcts. Cephalalgia 2005; 25: 369-77.
10. Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 2007; 140: 185-91.
11. Boni LJ, Ploug KB, Olesen J, Jansen-Olesen I, Gupta S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 2009; 29: 837-47.
12. Burgos JR, Iresjö BM, Smedh U. Pituitary adenylate cyclase-activating polypeptide 6-38 blocks cocaine-and amphetamine-regulated transcript peptide-induced hypophagia in rats. PLoS One 2013; 8: e72347.
13. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202-6.
14. Brandes JL, Visser WH, Farmer MV, Schuhl AL, Malbecq W, Vrijens F, et al. Montelukast for migraine prophylaxis: a randomized , doubleblind, placebo-controlled study. Headache 2004; 44: 581-6.
15. Chan KY, Baun M, de Vries R, van den Bogaerdt AJ, Dirven CMF, Danser AHJ, et al. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 2011; 31: 181-9.
16. Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, et al. Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviours in both inflammatory and neuropathic pain states. J Pain 2008; 9: 449-56.
17. de Koning PJ, Schaap JA, Janssen JP, Westenberg JJ, van der Geest RJ, Reiber JH. Automated segmentation and analysis of vascular structures in magnetic resonance angiographic images. Mag Reson Med 2003; 50: 1189-98.
18. Dickinson T, Fleetwood-Walker SM. VIP and PACAP: very important in pain? Trends Pharmacol Sci 1999; 20: 324-9.
19. Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell SJ, Lux G, Strunz U. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 1978; 19: 1049-53.
20. Edvinsson L. Role of VIP/PACAP in primary headaches. Cephalalgia 2013; 33: 1070-72.
21. Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 2000; 20: 1205-14.
22. Grä nde G, Nilsson E, Edvinsson L. Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myograph and pressurized cerebral artery method. Cephalalgia 2012; 33: 152-9.
23. Halvorson LM. PACAP modulates GnRH signaling in gonadotropes. Mol Cell Endocrinol 2013, in press. [doi: 10.1016/j.mce.2013.09.029. Epub ahead of print]
24. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 2006; 26: 992-1003.
25. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012; 166: 4-17.
26. Headache Classification Committee of the International Headache Society. International Classification of Headache Disorders. Cephalalgia 2004; 24: 24-5.
27. Hogan AD, Schwartz LB. Markers of mast cell degranulation. Methods 1997; 13: 43-52.
28. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38: 17-24.
29. Jongsma H, Danielsen N, Sundler F, Kanje M. Alteration of PACAP distribution and PACAP receptor binding in the rat sensory nervous system following sciatic nerve transection. Brain Res 2000; 853: 186-96.
30. Jongsma H, Pettersson LM, Zhang Y, Reimer MK, Kanje M, Waldenström A, et al. Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. Neuroreport 2001; 12: 2215-9.
31. Knutsson M, Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 2002; 13: 507-9.
32. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007; 130: 166-76.
33. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT1B/1D receptor agonists. Proc Natl Acad Sci USA 2004; 101: 4274-9.
34. Liu NJ, Schnell SA, Schulz S, Wessendorf MW, Gintzler AR. Regulation of spinal dynorphin 1-17 release by endogenous pituitary adenylyl cyclase-activating polypeptide in the male rat: relevance of excitation via disinhibition. J Pharmacol Exp Ther 2011; 336: 328-35.
35. Maejima Y, Shimomura K, Sakuma K, et al. Paraventricular nucleus nesfatin-1 neurons are regulated by pituitary adenylate cyclase-activating polypeptide (PACAP). Neurosci Lett 2013; 551: 39-42.
36. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-5.
37. Mustafa T. Pituitary adenylate cyclase-activating polypeptide (PACAP): a master regulator in central and peripheral stress responses. Adv Pharmacol 2013; 68: 445-57.
38. Petersen KA, Birk S, Kitamura K, Olesen J. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia 2009; 29: 23-30.
39. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilatation, but does not induce migraine. Cephalalgia 2008; 28: 226-36.
40. Resch JM, Maunze B, Gerhardt AK, Magnuson SK, Phillips KA, Choi S. Intrahypothalamic pituitary adenylate cyclase-activating polypeptide regulates energy balance via site-specific actions on feeding and metabolism. Am J Physiol Endocrinol Metab 2013; 305: E1425-52.
41. Schoonman GG, van der Grond J, Kortmann R, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 2008; 131: 2192-200.
42. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009; 132: 16-25.
43. Schytz HW, Olesen J, Ashina M. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics 2010; 7: 191-6.
44. Tajti J, Uddman R, Möller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999; 76: 176-83.
45. Taylor RD, Madsen MG, Krause M, Sampedro-Castaneda M, Stocker M, Pedarzani P. Pituitary adenylate cyclase-activating polypeptide (PACAP) inhibits the slow afterhyperpolarizing currect sIAHP in CA1 pyramidal neurons by activating multiple signaling pathways. Hippocampus 2014; 24: 32-43[doi: 10.1002/hipo.22201. Epub ahead of print].
46. Tfelt-Hansen PC. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review. Cephalalgia 2013; 33: 1122-31.
47. Thomas RL, Crawford N, Grafer C, Zheng W, Halvorson L. GATA augments GnRH-mediated increases in Adycyap1 gene expression in pituitary gonadotrope cells. J Mol Endocrinol 2013; 51: 313-24.
48. Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsányi J, Szabó N, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013; 33: 1085-95.
49. Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L. Neuropeptide expression in the human nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002; 22: 112-6.
50. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009; 61: 283-357.
51. Wolff HG. Headache and other head pain. New York, NY: Oxford University Press; 1963.